Tech Company Inital Public Offerings

Syndax Pharmaceuticals IPO

Syndax Pharmaceuticals, based in Waltham, debuted as a public company on 3/2/2016.

Transaction Overview

Announced On
3/2/2016
Transaction Type
IPO
Amount
$52,800,000
Proceeds Purpose
The principal purposes of this offering are to obtain additional capital to support our operations, establish a public market for our common stock and to facilitate our future access to the public capital markets. We currently expect to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments, for the following purposes: approximately $28.0 million to support the clinical trials of entinostat in combination with Keytruda® (pembrolizumab), atezolizumab and avelumab through the expected completion date of the two Phase 2 clinical trials; approximately $10.0 million to support additional clinical trials of entinostat in combination with immune checkpoint inhibitors; approximately $19.0 million to support the Phase 3 clinical trial of entinostat in advanced HR+ breast cancer through the primary endpoint of overall survival data; approximately $16.0 million to conduct activities to support the filing of a New Drug Application for

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Totten Pond Road 110
Waltham, MA 02451
USA
Email Address
Overview
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a Waltham, MA-based, oncology-focused biotechnology company that is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens.
Profile
Syndax Pharmaceuticals LinkedIn Company Profile
Social Media
Syndax Pharmaceuticals Company Twitter Account
Company News
Syndax Pharmaceuticals News
Facebook
Syndax Pharmaceuticals on Facebook
YouTube
Syndax Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Briggs Morrison
  Briggs Morrison LinkedIn Profile  Briggs Morrison Twitter Account  Briggs Morrison News  Briggs Morrison on Facebook
Chief Financial Officer
Allan Shaw
  Allan Shaw LinkedIn Profile  Allan Shaw Twitter Account  Allan Shaw News  Allan Shaw on Facebook
Chief Technical Officer
Peter Ordentlich
  Peter Ordentlich LinkedIn Profile  Peter Ordentlich Twitter Account  Peter Ordentlich News  Peter Ordentlich on Facebook
President
Michael Metzger
  Michael Metzger LinkedIn Profile  Michael Metzger Twitter Account  Michael Metzger News  Michael Metzger on Facebook
VP - Operations
Jeannette Hasapidis
  Jeannette Hasapidis LinkedIn Profile  Jeannette Hasapidis Twitter Account  Jeannette Hasapidis News  Jeannette Hasapidis on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/2/2016: Videogram venture capital transaction
Next: 3/2/2016: Bolstr venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary